Internal Medicine, Gastroenterology · Syosset, NY
NPI
1003913682
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
237 Jericho Turnpike
Syosset, NY, 11791
Phone (516) 584-6400
Groups this clinician bills Medicare through
Medicare paid, 2024
$423K
3,578 services
Medicare patients, 2024
953
Average age 76
Drug cost, 2024
$1.3M
3,066 prescriptions
Company payments, 2025
$6,772
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kostas Sideridis was code 99215 (office e&m - established), 768 times for 354 patients. In total Kostas Sideridis billed 3,578 services in 67 codes, and Medicare paid $423K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-06-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 768 | 354 | $161.05 | $124K |
| 99232 Hospital E&M - Subsequent | Facility | 726 | 307 | $69.14 | $50K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 303 | 131 | $14.54 | $4,405 |
| 99497 Care Management/Coordination | Facility | 294 | 270 | $66.50 | $20K |
| 99223 Hospital E&M - Initial | Facility | 230 | 218 | $152.58 | $35K |
| 96360 Intravenous Infusion, Hydration | Office | 207 | 173 | $29.60 | $6,126 |
| 99233 Hospital E&M - Subsequent | Facility | 144 | 83 | $104.91 | $15K |
| 99205 Office E&M - New | Office | 143 | 143 | $199.09 | $28K |
| 99214 Office E&M - Established | Office | 121 | 60 | $113.94 | $14K |
| 43239 Upper GI Endoscopy | Office | 97 | 94 | $335.97 | $33K |
| 45380 Lower GI Endoscopy - Other | Office | 94 | 92 | $413.83 | $39K |
| 43239 Upper GI Endoscopy | Facility | 58 | 54 | $72.75 | $4,220 |
| 99213 Office E&M - Established | Office | 53 | 38 | $75.16 | $3,983 |
| 96374 Injection Administration | Office | 34 | 29 | $33.16 | $1,127 |
| 45380 Lower GI Endoscopy - Other | Facility | 33 | 32 | $133.11 | $4,393 |
By year: 2022 $472K for 4,072 services; 2023 $444K for 3,286 services; 2024 $423K for 3,578 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 87635 COVID Specific | 78 | 69 | $50.28 | $3,922 |
Medicare prescription drug claims, 2024
In 2024, the drug Kostas Sideridis prescribed most often to Medicare patients was Pantoprazole Sodium, with 789 prescriptions and refills. In total Kostas Sideridis wrote 3,066 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 789 | 1,526 | 285 | $8,705 |
| Sucralfate Generic | 364 | 748 | 167 | $12K |
| Cholestyramine Cholestyramine (With Sugar) | 117 | 139 | 46 | $5,618 |
| Omeprazole Generic | 116 | 218 | 54 | $1,692 |
| Famotidine Generic | 111 | 171 | 39 | $887 |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 104 | 115 | 102 | $6,024 |
| Dicyclomine Hcl Generic | 96 | 140 | 37 | $1,538 |
| Linzess Linaclotide | 77 | 105 | 24 | $55K |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 65 | 65 | 23 | $1,289 |
| Enulose Lactulose | 57 | 58 | Under 11 | $376 |
| Ursodiol Generic | 50 | 74 | 17 | $28K |
| Ondansetron Hcl Ondansetron Hcl/Pf | 47 | 47 | Under 11 | $369 |
| Ondansetron Hcl Generic | 46 | 60 | 20 | $1,020 |
| Ondansetron Odt Ondansetron | 45 | 53 | 24 | $1,221 |
| Mesalamine Er Mesalamine | 41 | 69 | Under 11 | $13K |
Brand drugs: - claims; generic drugs: 2,476 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kostas Sideridis $6,772 ($6,772 in general payments such as food, travel and fees) from 20 companies. The largest payer was Intra-Sana Laboratories with $2,841.
| Company | Payments | Amount |
|---|---|---|
| Intra-Sana Laboratories | 6 | $2,841 |
| Abbvie Inc. ABBV | 37 | $695 |
| Madrigal Pharmaceuticals MDGL | 13 | $581 |
| Genzyme Corporation SNY | 12 | $454 |
| Janssen Biotech, Inc. JNJ | 12 | $423 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 26 | $351 |
| Ardelyx, Inc. ARDX | 8 | $213 |
| Pfizer Inc. PFE | 4 | $185 |
| Enterra Medical, Inc. | 2 | $175 |
| QOL Medical, LLC | 5 | $161 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.